We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
Read MoreHide Full Article
On Jan 18, we issued an updated research report on Neogen Corporation (NEOG - Free Report) . The company’s animal genomic business has developed rapidly with worldwide growth of 8% in the fiscal second quarter. However, the company operates in a highly competitive landscape. The stock currently carries a Zacks Rank #3 (Hold).
Shares of Neogen have underperformed its industry over the past six months. The stock has declined 26.6% in comparison with the industry’s 5% fall.
Neogen’s animal genomic business has been seeing strong growth. Also, the company’s beef genomics business performed well in the last reported quarter, including both the beef breed associations and for commercial producers.
The business, which originated in Lincoln Nebraska, has so far expanded well over the last few years, as the company continued to add laboratory capabilities in Scotland to serve the growing European market, purchased Deoxi lab, a genomic laboratory in Brazil, and moved into Australia, acquiring the genomics business from Queensland University in September 2017. This apart, the company has established a laboratory in Shanghai, China.
We are also upbeat about Neogen’s solid global business where revenues increased 10% from a year ago in the fiscal second quarter. This segment accounted for 39% of total revenues in the last reported quarter. According to Neogen, in recent times, international business is growing at a faster pace than the overall business.
The company is also bullish about the growth prospects in China and India. Neogen expects an increase in both the country’s middle-class points to lead to a rise in demand for higher-quality foods, including animal protein and dairy products.
Meanwhile, Neogen faces intense competition from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition from the development of new technologies by its competitor. Going forward this can affect the marketability and profitability of Neogen’s products.
Omnicell’s long-term earnings growth rate is projected at 11.8%. The stock carries a Zacks Rank #2 (Buy).
Illumina’s long-term earnings growth rate is expected at 23.4%. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
On Jan 18, we issued an updated research report on Neogen Corporation (NEOG - Free Report) . The company’s animal genomic business has developed rapidly with worldwide growth of 8% in the fiscal second quarter. However, the company operates in a highly competitive landscape. The stock currently carries a Zacks Rank #3 (Hold).
Shares of Neogen have underperformed its industry over the past six months. The stock has declined 26.6% in comparison with the industry’s 5% fall.
Neogen’s animal genomic business has been seeing strong growth. Also, the company’s beef genomics business performed well in the last reported quarter, including both the beef breed associations and for commercial producers.
The business, which originated in Lincoln Nebraska, has so far expanded well over the last few years, as the company continued to add laboratory capabilities in Scotland to serve the growing European market, purchased Deoxi lab, a genomic laboratory in Brazil, and moved into Australia, acquiring the genomics business from Queensland University in September 2017. This apart, the company has established a laboratory in Shanghai, China.
We are also upbeat about Neogen’s solid global business where revenues increased 10% from a year ago in the fiscal second quarter. This segment accounted for 39% of total revenues in the last reported quarter. According to Neogen, in recent times, international business is growing at a faster pace than the overall business.
The company is also bullish about the growth prospects in China and India. Neogen expects an increase in both the country’s middle-class points to lead to a rise in demand for higher-quality foods, including animal protein and dairy products.
Meanwhile, Neogen faces intense competition from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition from the development of new technologies by its competitor. Going forward this can affect the marketability and profitability of Neogen’s products.
Key Picks
Some better-ranked stocks in the broader medical space include Veeva Systems (VEEV - Free Report) , Omnicell, Inc. (OMCL - Free Report) and Illumina, Inc. (ILMN - Free Report) .
Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Omnicell’s long-term earnings growth rate is projected at 11.8%. The stock carries a Zacks Rank #2 (Buy).
Illumina’s long-term earnings growth rate is expected at 23.4%. The stock carries a Zacks Rank of 2.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>